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During pregnancy, growth of new blood vessels into the 
placenta is required to nourish the developing fetus. On page 
2165, Girardi et al. show that activation of the complement 
cascade blunts placental development by triggering the 
production of a potent angiogenesis inhibitor. Monitoring 
levels of complement activation in pregnant women might 
thus be useful in predicting pregnancy complications.
This group had previously shown that inhibition of 
complement activation prevented pregnancy loss in an antibody-
dependent mouse model of miscarriage. But they understood 
neither what triggered complement activation nor how 
complement interfered with normal fetal development.
Girardi and colleagues now solve half the mystery in a model 
of spontaneous miscarriage. Complement activation, they show, 
triggers the production of a decoy receptor—soluble vascular 
endothelial growth factor receptor-1 (sVEGFR-1)—that sops up the 
vessel-building protein 
VEGF, which is needed 
to establish the 
placental blood supply. 
Blocking complement 
activation inhibited the 
production of sVEGFR-1 
and restored normal 
fetal development. The 
in vivo cellular source of 
sVEGFR-1 was not 
identified, but monocytes are a good candidate, as these cells 
produced sVEGFR-1 in vitro when stimulated with complement.
During pregnancy, excessive inflammation—and the resulting 
complement activation—may create conditions unfavorable for 
the pregnancy to proceed. 
Sympathy for t-PA
Tissue plasminogen activator (t-PA), a protease 
released by vascular endothelial cells, keeps blood 
flowing freely by busting up clots. But t-PA is also 
produced by sympathetic nerve endings where, 
according to Schaefer et al. on page 2191, it en-
hances the release of norepinephrine (NE), which 
can cause the heart to beat erratically.
The clot-busting power of t-PA—which works 
by cleaving the proenzyme plasminogen into the 
active plasmin that then breaks down the clot 
protein fibrin—is often used to dissolve clots in 
patients who have had heart attacks or strokes. 
But treatment with recombinant t-PA has been 
associated with erratic heartbeats (or arrhythmias)—
a common cause of death post–heart attack.
The team now shows that the production of 
t-PA causes sympathetic nerve endings in the heart 
to release NE. And NE, which constricts vessels 
and increases heart rate, is known to trigger ar-
rhythmias. Indeed, mice lacking t-PA produced 
lower levels of NE and were less likely to develop 
arrhythmias after ischemic heart injury.
t-PA did not need to cleave plasminogen to 
induce NE release, but this activity did involve 
both Ca2+-dependent exocytosis and carrier-
dependent transport of NE from nerve endings. 
Exactly how this process gets started remains ob-
scure, in part because plasminogen is thus far the 
only known t-PA substrate.
Sympathetic nerve endings, which are abun-
dant in vessel walls and heart tissue, may produce 
t-PA to magnify fibrin breakdown in response 
to injury. But the secondary release of NE might 
then contribute to the arrhythmia often associ-
ated with therapeutic t-PA. 
Can DCs forecast atherosclerosis?
Atherosclerotic lesions are initiated mostly at vessel branch points 
and curvatures, where blood flow is irregular and inflammatory gene 
expression is high. Circulating blood cells—including macrophages, 
T cells, and dendritic cells (DCs)—accumulate in these areas at steady 
state, creating a scaffold on which the lesion is built. On page 2073, 
Jongstra-Bilen et al. suggest that it is DC build-up that most portends 
future lesion development.
Although many cell types have been shown to congregate in lesion-
prone regions of vessels, few studies have analyzed the relative 
abundance of these cell types in lesion-prone and lesion-resistant regions. 
Nor have they compared the cellular composition in atherosclerosis-
susceptible and -resistant strains of mice.
Jongstra-Bilen and colleagues now show that, in normal mice, DCs 
(but not T cells) were 100 times more abundant in lesion-prone areas 
of the aorta than in resistant areas. But these cells were found only in 
the innermost vessel layer (the intima). In the outermost layer (the 
adventitia), the cellular composition (mostly macrophages and T cells) 
was comparable in lesion-prone and -resistant regions.
These strategically located DCs were more plentiful in atherosclerosis-
prone mice than in resistant 
mice, suggesting that a 
preponderance of intimal 
DCs might predispose them 
toward atherosclerosis. The 
authors speculate that the 
DCs, which are adept at 
gobbling up macromolecules, 
might take up oxidized 
lipoproteins. Lipid-laden 
macrophages are important 
building blocks of athero-
sclerotic plaques—but perhaps 
these cells get in on the act 
only after lipid-stuffed DCs 
set the foundation. 
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Dendritic cells (green) are abundant in 
atherosclerosis-prone vessel regions.
Complement activation causes embryo loss 
(asterisks) in mouse uteri.